Gilead initiated with a Strong Buy at Raymond James. Raymond James analyst Steven Seedhouse initiated Gilead with a Strong Buy and $93 price target. The analyst believes the HCV business has stabilized, and said the strong Biktarvy launch in HIV and the continued impressive HIV prophylaxis segment suggests the HIV franchise has a long, lucrative tail. Seedhouse is confident in CAR-T platform and filgotinib opportunities, more so than from NASH and MMP9 in gastric cancer, but thinks Phase 3 NASH and MMP9 trials might still work.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.